Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer Meeting Abstract
| Authors: | Besse, B.; Eaton, K. D.; Soria, J. C.; Lynch, T. J.; Miller, V.; Wong, K. K.; Powell, C; Quinn, S.; Zacharchuk, C.; Sequist, L. V. |
| Abstract Title: | Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer |
| Meeting Title: | 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | EJC Supplements |
| Volume: | 6 |
| Issue: | 12 |
| Meeting Dates: | 2008 Oct 21-24 |
| Meeting Location: | Geneva, Switzerland |
| ISSN: | 1359-6349 |
| Publisher: | Pergamon-Elsevier Science Ltd |
| Date Published: | 2008-10-01 |
| Start Page: | 64 |
| Language: | English |
| ACCESSION: | WOS:000261221200201 |
| DOI: | 10.1016/s1359-6349(08)72135-9 |
| PROVIDER: | wos |
| Notes: | --- - Meeting Abstract - 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - OCT 21-24, 2008 - Geneva, SWITZERLAND - "Source: Wos" |
